TimothyFrancisCloughesyMD

Neurology • Los Angeles, CA

Neurooncology

Professor of Neuology/Director, UCLA NeuroOncology Program

Join to view full profile

Dr. Cloughesy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cloughesy's full profile

Already have an account?

Office
300 Medical Plaza Suite B200
Los Angeles, CA 90095
Phone+1 310-794-1195

Fax+1 310-794-7491

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Neurology, 1988 - 1991
Creighton University School of Medicine/Maricopa Medical Center (Phoenix)Internship, Internal Medicine, 1987 - 1988
Tulane University School of MedicineClass of 1987

Certifications & Licensure

CA State Medical License 1988 - 2026
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
Top Doctors:LA Area Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma Start of enrollment: 2000 May 16
Completed
Phase 1, Phase 2
Sirolimus in Treating Patients With Glioblastoma Multiforme Start of enrollment: 2002 Jul 01
Completed
Phase 1, Phase 2
Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Start of enrollment: 2002 Sep 01
Completed
Phase 1
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer Start of enrollment: 2002 Sep 01
Completed
Not Applicable
Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma Start of enrollment: 2004 May 01
Completed
Phase 1, Phase 2
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM) Start of enrollment: 2004 Jan 01
Completed
Phase 1, Phase 2
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma Start of enrollment: 2006 Aug 01
Completed
Phase 1
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2010 Jul 01
Completed
Phase 2
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM Start of enrollment: 2013 Dec 09
Completed
Phase 2
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Start of enrollment: 2014 Feb 07
Active, not recruiting
Phase 3
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma Start of enrollment: 2014 Mar 13
Active, not recruiting
Phase 1
Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2002 Sep 01
Completed
Phase 1
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Start of enrollment: 2015 Nov 30
Terminated
Phase 2, Phase 3
Terameprocol in Treating Patients With Recurrent High Grade Glioma Start of enrollment: 2018 May 03
Completed
Phase 1
Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Start of enrollment: 2018 Oct 30
Terminated
Phase 1
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma Start of enrollment: 2019 Dec 01
Withdrawn
Phase 2
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma Start of enrollment: 2018 Nov 28
Active, not recruiting
Phase 2
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma Start of enrollment: 2020 Jan 08
Recruiting
Phase 1
A Study of Abemaciclib in Recurrent Glioblastoma Start of enrollment: 2017 Feb 09
Active, not recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

18 citations
Correcting the drug development paradigm for glioblastoma requires serial tissue sampling.
Kirit Singh, Kelly M Hotchkiss, Ian F Parney, John De Groot, Solmaz Sahebjam
Nature Medicine. 2023-10-01
872 citations
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Timothy F. Cloughesy, Aaron Mochizuki, Joey Orpilla, Willy Hugo, Alexander Lee
Nature Medicine. 2019-02-11
131 citations
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
Andrew D. Norden, Jeffrey J. Raizer, Lauren E. Abrey, Kathleen R. Lamborn, Andrew B. Lassman
Journal of Neuro-Oncology. 2010-01-01

Press Mentions

Kazia Executes Agreement to Commence GBM Agile Pivotal StudyOctober 16th, 2020
Kazia Therapeutics Executes Agreement to Begin GBM Agile Pivotal StudyOctober 15th, 2020
Toca 5 Phase 3 Trial Results Presented at the Society for Neuro-Oncology Annual MeetingNovember 22nd, 2019
Join now to see all

Grant Support

UCLA IRB 08-09-042: Phase I Trial Of Aflibercept (Vegf Trap) With Radiation TheNational Center For Research Resources2010
UCLA IRB # 06-04-104 "A Phase I/II, Dual-Center, Open-Label Trial Of The SAFENational Center For Research Resources2009–2010
UCLA IRB # 06-04-016 "Phase II Trial Of Bevacizumab In Combination With TemozNational Center For Research Resources2007–2010
Phase I/II Study Of OSI-774 (ERLOTINIB) And CCI-779 (TEMSIROLIMUS) In PatientNational Center For Research Resources2007–2010
Phase II Single Arm Trial Of VEGF TRAP In Patients With Recurrent Temozolomide-National Center For Research Resources2009
UCLA IRB (PENDING) "A Phase I/II Studies Of BAY 43-9006 (SORAFENIB) In CombinNational Center For Research Resources2007–2009
UCLA IRB #05-12-061 "A Phase I Study Of Vorinostat (Suberoylanilide HydroxamiNational Center For Research Resources2007–2009
Recurrent Temozolomide-Resistant Malignant GliomasNational Center For Research Resources2008
Clinical Trial: A Phase II Trial Of Poly-Iclc In Patients With Recurrent AnaplasNational Center For Research Resources2008
"A Phase I/II Studies Of BAY 43-9006 (SORAFENIB) In CombinNational Center For Research Resources2008
A Biomarker And Phase II Study Of GW 572016 In Recurrent Malignant Glioma (NaNational Center For Research Resources2007–2008
Consortium Therapeutic Studies Of Primary Central Nervous System MalignanciesNational Cancer Institute2007–2008
Consortium Therapeutic Studies Of Primary Central Nervi*National Center For Research Resources2005–2008
Phase II Trial Of EMD 121974 For Recurrent Glioblastoma: A Clinical Trial WitNational Center For Research Resources2006–2007
A Phase II Trial Of Poly-Iclc In Patients With Recurrent Anaplastic Glioma NNational Center For Research Resources2005–2007
A Multicenter, Open-Label, Randomized, Uncontrolled, Phase IIA Trial In SubjeNational Center For Research Resources2006
ZD1839 For Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or GLINational Center For Research Resources2005–2006
A Phase II Trial Of STI-571 ( NSC 716051) In Patients With Recurrent MeningioNational Center For Research Resources2005–2006
A Phase I/II Trial Of OSI-774 In Patients With Recurrent Malignant Gliomas AnNational Center For Research Resources2005–2006
A Modified Phase I/II Trial Of Rapamycin In Patients With Malignant GliomasNational Center For Research Resources2005–2006
Consortium Therapeutic Studies Of Primary Central Nervi*National Cancer Institute2005–2006
Phase II Trial Of Poly-Iclc For Glioblastoma [Nabtc 01-05]National Center For Research Resources2005
Phase I/II Of R115777 In Patients With Recurrent Malignant GliomasNational Center For Research Resources2005
Phase I-II Trial Of STI-571 (Nsc 716051) In Patients With Recurrent MalignantNational Center For Research Resources2005
ZD1839 For Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Gli...National Center For Research Resources2004
Quantified Gene Expression Improves PrognosisNational Center For Research Resources2004
Phase II Evaluation Of Fenretinide (Nsc 374551) As A SNational Center For Research Resources2004
Phase I/II Trial Of OSI-774 In Patients With RecurrentNational Center For Research Resources2004
Phase I/II Trial Of CCI-779 In Patients With Malignant Gliomas (Nabtc 01-01)National Center For Research Resources2004
Phase I/II Of R115777 For Recurrent Malignant GliomasNational Center For Research Resources2004
Modified Phase I/II Trial Of Rapamycin In Patients WitNational Center For Research Resources2004
Consortium Therapeutic Studies Of CNS MalignanciesNational Cancer Institute2004
Gene Expression Prognosis &Trtmt Response Stratification In PATS W/ GliomaNational Center For Research Resources1999–2002
Phase I/II Trial Of Ironstecan In Patients With GliomaNational Center For Research Resources2001
Phase 2 Trial Of Thymidine/Carboplatin Therapy Of GliomaNational Center For Research Resources2001
Quantify Gene Expression: Prognosis &Therapy Response Stratification In GliomaNational Center For Research Resources1998

TimothyFrancisCloughesyMD

Dr. Cloughesy is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.